FME 📈 Fresenius Medical Care AG - Overview

Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE0005785802

FME: Dialysis Machines, Dialyzers, Solutions, Pharmaceuticals, Systems, Services

Fresenius Medical Care AG & Co. KGaA is a leading provider of dialysis and related services for individuals with renal diseases globally. With a strong presence in Germany, North America, and internationally, the company operates a vast network of outpatient dialysis clinics, offering comprehensive treatment and laboratory services to patients.

In addition to its clinic-based services, Fresenius Medical Care provides a range of support services, including clinical monitoring, follow-up assistance, and home delivery of medical supplies. The company also partners with hospitals in the United States to provide dialysis services to hospitalized patients with end-stage renal disease (ESRD) and acute kidney failure.

The company's product portfolio is equally impressive, with a focus on developing, manufacturing, and distributing a wide range of healthcare products. These include polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, and other essential equipment for dialysis treatment. Additionally, Fresenius Medical Care offers a variety of renal pharmaceuticals, solutions, and granulates, as well as systems for water treatment and acute cardiopulmonary and apheresis products.

Fresenius Medical Care's commitment to innovation extends to the development, acquisition, and in-licensing of new renal pharmaceuticals. The company also provides renal medications and supplies directly to patients' homes or to dialysis clinics. Furthermore, Fresenius Medical Care offers a range of specialized services, including vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services.

In terms of sales and distribution, Fresenius Medical Care reaches its customers through a combination of direct sales, local sales forces, independent distributors, dealers, and sales agents. With a strong online presence, the company's website (https://www.freseniusmedicalcare.com) provides a wealth of information on its products and services.

Founded in 1996, Fresenius Medical Care AG & Co. KGaA is headquartered in Bad Homburg, Germany, and has established itself as a leader in the global dialysis and renal care market.

Additional Sources for FME Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

FME Stock Overview

Market Cap in USD 12,926m
Sector Healthcare
Industry Medical Care Facilities
GiC Industry Health Care Providers & Services
TER 0.00%
IPO / Inception

FME Stock Ratings

Growth 5y -33.1%
Fundamental 30.4%
Dividend 37.7%
Rel. Performance Sector 0.35
Analysts -
Fair Price Momentum 44.92 EUR
Fair Price DCF 162.35 EUR

FME Dividends

Dividend Yield 12m 2.68%
Yield on Cost 5y 2.10%
Annual Growth 5y -0.87%
Payout Consistency 97.58%

FME Growth Ratios

Growth Correlation 3m 71.6%
Growth Correlation 12m 34.5%
Growth Correlation 5y -79.1%
CAGR 5y -4.69%
CAGR/Mean DD 5y -0.15
Sharpe Ratio 12m 0.57
Alpha 3.59
Beta 0.37
Volatility 32.87%
Current Volume 425.5k
Average Volume 20d 403.9k
What is the price of FME stocks?
As of December 04, 2024, the stock is trading at EUR 44.43 with a total of 425,470 shares traded.
Over the past week, the price has changed by -3.26%, over one month by +14.47%, over three months by +20.02% and over the past year by +12.69%.
Is Fresenius Medical Care AG a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Fresenius Medical Care AG is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 30.39 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FME as of December 2024 is 44.92. This means that FME is currently overvalued and has a potential downside of 1.1%.
Is FME a buy, sell or hold?
Fresenius Medical Care AG has no consensus analysts rating.
What are the forecast for FME stock price target?
According to ValueRays Forecast Model, FME Fresenius Medical Care AG will be worth about 48.5 in December 2025. The stock is currently trading at 44.43. This means that the stock has a potential upside of +9.21%.
Issuer Forecast Upside
Wallstreet Target Price 39.9 -10.1%
Analysts Target Price - -
ValueRay Target Price 48.5 9.2%